Keenova's Strong Fourth Quarter Performance Reflects Brand Transition Success Keenova Therapeutics showcases impressive Q4 results, driven by strong sales in Acthar Gel and XIAFLEX, as the company transitions successfully into a branded therapeutics entity.

Keenova's Strong Fourth Quarter Performance Reflects Brand Transition Success #Ireland #Dublin #XIAFLEX #Acthar_Gel #Keenova

Mallinckrodt's Q3 2025 Financial Results Show Significant Sales Growth and Strategic Merger Impact Mallinckrodt reports impressive financial results for Q3 2025 with $753.1 million in sales, primarily driven by Acthar Gel and the recent merger with Endo. The company outlines future expectations.

Mallinckrodt's Q3 2025 Financial Results Show Significant Sales Growth and Strategic Merger Impact #Ireland #Dublin #Mallinckrodt #Acthar_Gel #Keenova_Therapeutics

Exploring Treatment Patterns and Outcomes with Acthar Gel for Arthritis Patients Mallinckrodt plc reveals findings on the effectiveness of Acthar Gel in managing symptoms for patients with ankylosing spondylitis and psoriatic arthritis.

Exploring Treatment Patterns and Outcomes with Acthar Gel for Arthritis Patients #United_States #Dublin #Mallinckrodt #Acthar_Gel #Arthritic_Treatment

Mallinckrodt plc Reports Q2 2025 Financial Results and Future Outlook Mallinckrodt plc announces its financial results for the second quarter of 2025, marking a revenue dip but strong performance in key areas amidst a significant merger.

Mallinckrodt plc Reports Q2 2025 Financial Results and Future Outlook #None #Mallinckrodt #Endo #Acthar_Gel

Mallinckrodt Unveils Positive Patient Feedback on Acthar® Gel SelfJect Injector Experience Discover the recent survey findings published by Mallinckrodt that highlight patient satisfaction with the Acthar® Gel SelfJect Injector, showcasing ease of use and confidence among users.

Mallinckrodt Unveils Positive Patient Feedback on Acthar® Gel SelfJect Injector Experience #Ireland #Dublin #Mallinckrodt #Acthar_Gel #SelfJect

Real-World Outcomes of Acthar Gel Presented at LUPUS 2025 Conference Mallinckrodt highlights real-world data on Acthar Gel for systemic lupus erythematosus at LUPUS 2025, showcasing treatment effectiveness and patient profiles.

Real-World Outcomes of Acthar Gel Presented at LUPUS 2025 Conference #Canada #Toronto #Mallinckrodt #Acthar_Gel #Systemic_Lupus

Mallinckrodt plc Reports Strong First Quarter 2025 Financials and Outlines Positive Future Expectations Mallinckrodt plc has reported its Financial Results for the first quarter of 2025, showing key areas of growth and reaffirming its full-year guidance amidst ongoing challenges.

Mallinckrodt plc Reports Strong First Quarter 2025 Financials and Outlines Positive Future Expectations #Ireland #Dublin #Mallinckrodt #Acthar_Gel #INOmax